Literature DB >> 18624307

Intrasplenic trafficking of natural killer cells is redirected by chemokines upon inflammation.

Claude Grégoire1, Céline Cognet, Lionel Chasson, Charles-Antoine Coupet, Marc Dalod, Andrea Reboldi, Jacqueline Marvel, Federica Sallusto, Eric Vivier, Thierry Walzer.   

Abstract

The spleen is a major homing site for NK cells. How they traffic to and within this site in homeostatic or inflammatory conditions is, however, mostly unknown. Here we show that NK cells enter the spleen through the marginal sinus and home to the red pulp via a pertussis toxin-insensitive mechanism. Upon inflammation induced by poly(I:C) injection or mouse cytomegalovirus infection, many NK cells left the red pulp while others transiently entered the white pulp, predominantly the T cell area. This migration was dependent on both CXCR3 and CCL5, suggesting a synergy between CXCR3 and CCR5, and followed the path lined by fibroblastic reticular cells. Thus, the entry of NK cells in the white pulp is limited by the expression of pro-inflammatory chemokines. This phenomenon ensures the segregation of NK cells outside of the white pulp and might contribute to the control of immunopathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18624307     DOI: 10.1002/eji.200838550

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

Review 1.  Boosting vaccine efficacy the natural (killer) way.

Authors:  Carolyn E Rydyznski; Stephen N Waggoner
Journal:  Trends Immunol       Date:  2015-08-10       Impact factor: 16.687

2.  CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection.

Authors:  R Keith Reeves; Jacqueline Gillis; Fay E Wong; Yi Yu; Michelle Connole; R Paul Johnson
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

3.  Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques.

Authors:  Jonathan E Feig; Sajesh Parathath; James X Rong; Stephanie L Mick; Yuliya Vengrenyuk; Lisa Grauer; Stephen G Young; Edward A Fisher
Journal:  Circulation       Date:  2011-02-21       Impact factor: 29.690

Review 4.  Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals.

Authors:  Rosa Barreira da Silva; Christian Münz
Journal:  Cell Mol Life Sci       Date:  2011-08-23       Impact factor: 9.261

Review 5.  NK cells in immunotolerant organs.

Authors:  Haoyu Sun; Cheng Sun; Zhigang Tian; Weihua Xiao
Journal:  Cell Mol Immunol       Date:  2013-04-08       Impact factor: 11.530

6.  IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection.

Authors:  Tsukasa Nabekura; Jean-Philippe Girard; Lewis L Lanier
Journal:  J Immunol       Date:  2015-04-29       Impact factor: 5.422

7.  Interferon-γ mediates chemokine-dependent recruitment of natural killer cells during viral infection.

Authors:  Melissa A Pak-Wittel; Liping Yang; Dorothy K Sojka; Joshua G Rivenbark; Wayne M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

8.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

9.  Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes.

Authors:  Aradhana Awasthi; Asanga Samarakoon; Haiyan Chu; Rajasekaran Kamalakannan; Lawrence A Quilliam; Magdalena Chrzanowska-Wodnicka; Gilbert C White; Subramaniam Malarkannan
Journal:  J Exp Med       Date:  2010-08-23       Impact factor: 14.307

10.  (19)F-MRI for monitoring human NK cells in vivo.

Authors:  Myriam N Bouchlaka; Kai D Ludwig; Jeremy W Gordon; Matthew P Kutz; Bryan P Bednarz; Sean B Fain; Christian M Capitini
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.